Physician profile
Gregory E Yager
NPI 1881787737
$10,048.99
in general payments reported to CMS, 2019-2025
24 companies · $1,239 in 2025
The $1,239 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,141 · 2020: $1,073 · 2021: $2,171 · 2022: $1,033 · 2023: $1,460 · 2024: $1,931 · 2025: $1,239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,630.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,286.89 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $1,953.55 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Biohaven Pharmaceuticals, INC. | $1,235.05 | 2021 | |
| Lilly USA, LLC | $553.17 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $444.07 | 2021-2025 | Ubrelvy, Qulipta |
| Amgen INC. | $416.56 | 2024-2025 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $326.85 | 2022-2025 | |
| Glaxosmithkline, LLC. | $267.36 | 2021-2024 | Arexvy, Shingrix, Fluarix Quadrivalent |
| Janssen Pharmaceuticals, INC | $252.83 | 2019-2020 | |
| Abbott Laboratories | $243.93 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Pfizer INC. | $222.65 | 2019-2024 | |
| Daiichi Sankyo INC. | $220.76 | 2024-2025 | Injectafer |
| Biohaven Pharmaceutical Holding Company Ltd. | $162.88 | 2022 | |
| Exact Sciences Corporation | $104.09 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $56.86 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $53.82 | 2023-2024 | Ztlido |
| Horizon Therapeutics Plc | $45.60 | 2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.76 | 2019 | |
| Dexcom, INC. | $42.63 | 2023-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $33.74 | 2024 | Veozah |
| Idorsia Pharmaceuticals US INC | $29.39 | 2023 | Quviviq |
| Intuitive Surgical, INC. | $22.43 | 2019 | |
| Merck Sharp & Dohme LLC | $20.00 | 2020 | |
| Sanofi-Aventis U.S. LLC | $11.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Yager listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.